NeuroLogica’s OmniTom Elite has received 510(k) clearance for the addition of Photon Counting Detector (PCD) technology.

The world of medical imaging is no longer just black & white. NeuroLogica Corp, a subsidiary of Samsung Electronics, announced today its state-of-the-art OmniTom Elite has received 510(k) clearance for the addition of Photon Counting Detector (PCD) technology. NeuroLogica delivers the first FDA 510(k) cleared, single-source photon counting computed tomography (CT) scanner with single detector. OmniTom Elite with PCD can generate spectral CT images at multiple energy levels.

Photon counting is a next-generation CT technology that sorts the different energies of X-rays after they have passed through the scan field. A single X-ray source paired with PCD generates multiple sets of CT data acquired at the same time with configurable energy thresholds without any cross talk between images. PCD provides the ability to capture CT data in multiple energy bands leading to potentially more accurate visualization and segmentation of bone, blood clots, plaque, hemorrhage and intracranial tumors. There is also potential with PCD to lower the dose requirements, and fundamentally change the use of injected contrast.

“NeuroLogica is driven by innovation. Since the advent of the world’s first multi-slice mobile CT in 2004, we have always known that point-of-care imaging can improve patient outcomes and increase the likelihood of a better quality of life after a traumatic event,” said David Webster, Chief Operating Officer of NeuroLogica. “With the introduction of PCD technology to the OmniTom Elite platform, we look to expand the diagnostic possibilities of CT at the patient’s bedside.”

The OmniTom Elite has the ability to provide versatile, real-time mobile imaging to administer point-of-care CT to critical patients without the need to transport them to a separate imaging department. The mobile unit will decrease the time it takes to diagnose and initiate treatment for these critical patients.

“Availability of photon-counting detector technology on a mobile head CT platform is a significant advance in the development of CT,” said Rajiv Gupta, PhD, MD, Neuroradiology Division Chief of Massachusetts General Hospital and Associate Professor at Harvard Medical School. “This advance heralds a new era of CT applications in stroke, trauma, ICU and intra-op settings.” MGH is collaborating with NeuroLogica and will pilot test the OmniTom Elite with PCD to monitor post-trauma and post-surgical patients.

Upgrading capabilities were top of mind when designing OmniTom Elite mobile CT scanners. In the near term, all current OmniTom users will have the opportunity to upgrade their scanners with this technology. Meanwhile, a limited number of premier research partners will aid in developing the full potential of OmniTom Elite with PCD.

Neurologica’s OmniTom Elite, and the entire mobile CT product line are manufactured in Danvers, MA, USA.

To stay informed about our PCD products, events and future developments please sign up on our website: https://www.neurologica.com/mobile-ct/PCD

About NeuroLogica

NeuroLogica Corp., the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica is the global corporate headquarters and manufacturer of mobile computed tomography devices. NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction and increase workflow efficiency. For more information, please visit: http://www.NeuroLogica.com.

The alliance, to be announced today at the North American Neuromodulation Society (NANS) Scientific Session in Las Vegas, will leverage Samsung’s deep understanding of consumer technology and mobility to develop advanced tools, based on the Android operating system, aimed at improving how patients and physicians interact with and receive data from Medtronic’s clinically-proven neuromodulation systems. By integrating neuromodulation therapies with Samsung technology, Medtronic seeks to deliver real-time health data to physicians and patients so they can more effectively manage the therapy, track symptoms and wirelessly monitor data received from Medtronic devices.

“Medtronic is committed to solving healthcare challenges, and through this alliance we intend to create efficiencies by developing digital solutions that connect patients and healthcare providers in real time,” said Tom Tefft, senior vice president and president of Neuromodulation, which is part of the Restorative Therapies Group at Medtronic. “Medtronic has a track record of developing meaningful patient innovations, and this collaboration is the first step to providing more personalized patient care and arming patients and physicians with the best consumer-relevant technologies.”

In the future, this alliance between Medtronic and Samsung is intended to focus on enabling patients implanted with neuromodulation therapies to use consumer electronics, such as smartphones, wearables or tablets, to securely and wirelessly transmit real-time data from their device to their physicians. Connecting patients and physicians in this manner could provide many potential benefits, including allowing physicians to more quickly make informed, data-driven treatment decisions.

“Samsung is applying its deep understanding of how people use technology to bring new innovations to healthcare,” said Dave Rhew, Chief Medical Officer and Head of Healthcare and Fitness for Samsung Electronics America. “These future solutions will help better manage the health of patients by providing them with advanced, easy-to-use tools that securely deliver real-time data to their physicians”.

In June 2015, Medtronic and Samsung announced a similar collaboration to enable solutions to improve diabetes management for the millions of people at risk and currently living with the disease.  The first project focuses on delivering more discreet and convenient access to personal diabetes data by developing mobile applications optimized for Samsung mobile devices that will enable the viewing of insulin pump and continuous glucose monitoring (CGM) sensor information.

About Medtronic Neuromodulation Solutions

Medtronic developed and leads the field of neuromodulation, the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system. The company’s Neuromodulation business includes medical systems for the management of chronic pain, movement disorders, severe spasticity and urologic and gastrointestinal disorders.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.